BridgeBio Oncology Therapeutics
(NASDAQ) BBOT
BridgeBio Oncology Therapeutics Financials at a Glance
Market Cap
$645.06M
Revenue (TTM)
$0.00
Net Income (TTM)
$134.04M
EPS (TTM)
$-1.50
P/E Ratio
-5.39
Dividend
$0.00
Beta (Volatility)
2.30 (High)
Dividend
$0.00
Beta (Volatility)
2.30 (High)
Price
$8.44
Volume
357,130
Open
$8.09
Price
$8.44
Volume
357,130
Open
$8.09
Previous Close
$8.41
Daily Range
$8.00 - $8.64
52-Week Range
$8.00 - $14.87
Dividend
$0.00
Beta (Volatility)
2.30 (High)
Price
$8.44
Volume
357,130
Open
$8.09
Previous Close
$8.41
Daily Range
$8.00 - $8.64
52-Week Range
$8.00 - $14.87
BBOT News
Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout BridgeBio Oncology Therapeutics
Industry
Biotechnology
Sector
Health CareEmployees
92
CEO
Eli M. Wallace, PhD
Website
bbotx.comHeadquarters
South San Francisco, CA 94080, US
BBOT Financials
Key Financial Metrics (TTM)
Gross Margin
0%
Operating Margin
0%
Net Income Margin
0%
Return on Equity
-28%
Return on Capital
-35%
Return on Assets
-30%
Earnings Yield
-18.55%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$645.06M
Shares Outstanding
80.03M
Volume
357.13K
Avg. Volume
316.86K
Financials (TTM)
Gross Profit
$610.00K
Operating Income
$145.82M
EBITDA
$145.82M
Operating Cash Flow
$113.89M
Capital Expenditure
$606.00K
Free Cash Flow
$114.50M
Cash & ST Invst.
$425.46M
Total Debt
$2.77M
BridgeBio Oncology Therapeutics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonCurrently no data to display.
Earnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$0.00
N/A
Gross Profit
$194.00K
N/A
Gross Margin
0.00%
N/A
Market Cap
$645.06M
N/A
Market Cap/Employee
$10.40M
N/A
Employees
62
N/A
Net Income
$38.80M
-97.1%
EBITDA
$43.21M
-98.0%
Quarterly Fundamentals
Net Cash
$422.69M
+24796.9%
Accounts Receivable
$386.00K
N/A
Inventory
$0.00
N/A
Long Term Debt
$2.24M
N/A
Short Term Debt
$522.00K
N/A
Return on Assets
-29.90%
N/A
Return on Invested Capital
-35.28%
N/A
Free Cash Flow
$55.55K
+36.8%
Operating Cash Flow
$375.55K
-327.4%